Search

Your search keyword '"Garralda E"' showing total 119 results

Search Constraints

Start Over You searched for: Author "Garralda E" Remove constraint Author: "Garralda E" Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
119 results on '"Garralda E"'

Search Results

1. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

5. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

6. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

7. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

10. 118O Definitive results for NSCLC and bladder cancer cohorts in the phase IIa trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)

11. 127P Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors

13. 223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST

15. 1295P EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI

16. 1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors

18. 664P Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)

27. 6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials

29. 2246P Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study

30. 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types

31. 1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)

33. 1056P Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)

42. 702P Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy

45. 538P Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials

Catalog

Books, media, physical & digital resources